XML 211 R87.htm IDEA: XBRL DOCUMENT
v3.25.1

Long-Term Investments - Schedule of Extent the Investee Relies (Details) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2025 | Dec. 31, 2024
Braingenesis Biotechnology Co., Ltd. [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | No specific business relationship | No specific business relationship
Genepharm Biotech Corporation [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | No specific business relationship | No specific business relationship
BioHopeKing Corporation [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements) | Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)
BioLite Japan K.K. [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | The Company’s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan | The Company’s joint venture noncontrolling subsidiary perform research and development activities and explore business opportunities in Japan
ForSeeCon Eye Corporation [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements) | Collaborating with the Company to develop and commercialize ophthalmic medical devices (referring to Note 4, Collaborative Agreements)
BioFirst Corporation [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | Loaned from the investee and provides research and development support service | Loaned from the investee and provides research and development support service
OncoX BioPharma, Inc. [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements) | Collaborating with the Company to develop and commercialize single-herb botanical drug for treatment of certain diseases (referring to Note 4, Collaborative Agreements)
Rgene Corporation [Member] |  |
Schedule of Extent the Investee Relies [Line Items] |  |
The extent the investee relies on the Company for its business, description | Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements) | Collaborating with the Company to develop and commercialize drugs (referring to Note 4, Collaborative Agreements)

X
- Definition A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481440/840-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479741/842-40-50-1 + Details
Name: | us-gaap_RelatedPartyTransactionDescriptionOfTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteJapanKKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_ForSeeConEyeCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_OncoXBioPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |